ALMAGEL PLUS SUS 200 MG / 5 ML
MAGNESIUM HYDROXIDE : 200 MG / 5 ML DIMETHICONE : 25 MG / 5 ML ALUMINUM HYDROXIDE : 200 MG / 5 ML · DIN 00815527 · LABORATOIRE ATLAS INC
Health Canada status: MARKETED
What is ALMAGEL PLUS SUS?
ALMAGEL PLUS SUS 200 MG / 5 ML contains MAGNESIUM HYDROXIDE : 200 MG / 5 ML DIMETHICONE : 25 MG / 5 ML ALUMINUM HYDROXIDE : 200 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 00815527, held by LABORATOIRE ATLAS INC, supplied as SUSPENSION for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Apr-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00815527 |
|---|---|
| Brand name | ALMAGEL PLUS SUS |
| Generic / active ingredient | MAGNESIUM HYDROXIDE : 200 MG / 5 ML DIMETHICONE : 25 MG / 5 ML ALUMINUM HYDROXIDE : 200 MG / 5 ML |
| Manufacturer | LABORATOIRE ATLAS INC |
| Strength | 200 MG / 5 ML |
| Dosage form | SUSPENSION |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02AF02 ORDINARY SALT COMBINATIONS AND ANTIFLATULENTS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 09-Apr-1997 |
What can be used instead?
Other Canadian products sharing ATC code A02AF02 ORDINARY SALT COMBINATIONS AND ANTIFLATULENTS. 4 of 56 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GELUSIL ANTACID AND ANTI-GAS | 25 MG | TABLET (CHEWABLE) | PHARMASCIENCE INC | MARKETED | DIN 02409836 |
| STOMAAX PLUS | 25 MG / 5 ML | SUSPENSION | LABORATOIRE ATLAS INC | MARKETED | DIN 00623709 |
| TUMS CHEWY BITES WITH GAS RELIEF | 750 MG | TABLET (CHEWABLE) | HALEON CANADA ULC | MARKETED | DIN 02540274 |
| ANTACID & ANTIGAS | 20.00 MG / 5 ML | SUSPENSION | GERI-CARE PHARMACEUTICALS CORP. | CANCELLED (UNRETURNED ANNUAL) | DIN 02410095 |
| ANTACID CHEWABLE TAB | 200 MG | TABLET | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | DIN 00391700 |
| ANTACID CHEWABLE TAB | 200 MG | TABLET | KSL PHARMACEUTICALS | CANCELLED POST MARKET | DIN 00886505 |
| ANTACID LIQUID SUSP | 200 MG / 5 ML | SUSPENSION | SHOPPERS DRUG MART INC. | CANCELLED POST MARKET | DIN 00417920 |
| ANTACID PLUS - SUS | 200 MG / 5 ML | SUSPENSION | WES PAK PRODUCTS LTD. | CANCELLED POST MARKET | DIN 02226855 |
| ANTACID PLUS ANTIFLATUENT | 200 MG / 5 ML | SUSPENSION | STANLEY PHARMACEUTICALS, A DIVISION OF VITA HEALTH PRODUCTS INC. | CANCELLED POST MARKET | DIN 00854638 |
| ANTACID PLUS ANTIFLATULENT | 25 MG / 5 ML | SUSPENSION | KSL PHARMACEUTICALS | CANCELLED POST MARKET | DIN 00849111 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.